Pharmaceuticals

Quit Smoking Drugs Market Outlook For 2026–2030 Covering Growth Drivers And Industry Trends

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Quit Smoking Drugs Market Expected To Reach Based On Its 2026 Value?

The quit smoking drugs market has experienced substantial expansion in recent years. This market is projected to grow from $44.23 billion in 2025 to $50.94 billion in 2026, showing a compound annual growth rate (CAGR) of 15.2%. The historical increase can be attributed to factors such as enhanced awareness of smoking’s dangers, the increasing occurrence of smoking-related illnesses, the widespread availability of nicotine replacement therapies, governmental initiatives against smoking, and the flourishing of pharmaceutical manufacturing in developing economies.

The quit smoking drugs market is poised for significant expansion over the coming years, with projections indicating a rise to $90.73 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.5%. This growth during the forecast period is primarily driven by advancements in digital health solutions, the increasing adoption of personalized medicine, the integration of AI in treatment monitoring, the expansion of telemedicine services, and the development of wearable health monitoring devices. Noteworthy trends expected during this period include personalized nicotine replacement therapies, mobile health (mHealth) and smoking cessation applications, telemedicine-driven prescription support, the integration of behavioral therapy with drug therapy, and wearable devices for monitoring cravings.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9247&type=smp

Which Strong Drivers Are Impacting The Quit Smoking Drugs Market Growth?

The increasing incidence of smoking dependency is projected to drive expansion in the quit-smoking drug market in the future. Smoking involves the act of inhaling and exhaling vapors from ignited plant materials like tobacco, marijuana, hashish, among others. Quit smoking drugs function by diminishing an individual’s desire to smoke and hindering tobacco cravings; these prescription medications help manage nicotine withdrawal signs, thereby facilitating successful smoking cessation. As an illustration, the OECD (Organisation for Economic Co-operation and Development), a France-based intergovernmental international organization, reported in November 2025 that 14.8% of individuals aged 15 and above engaged in daily smoking during 2023. The highest percentages of daily smokers were observed in Türkiye, Hungary, and Greece, along with accession/partner nations Indonesia, Bulgaria, and China, with at least one in four individuals smoking daily in these regions. In 2023, an average of 18.5% of men smoked daily, while the figure for women was 11.4%. Consequently, the rising occurrence of smoking addiction is propelling the expansion of the quit-smoking drug market.

How Is The Quit Smoking Drugs Market Categorized Across Its Segment Groups?

The quit smoking drugs market covered in this report is segmented –

1) By Product: Drug Therapy, E-Cigarettes, Nicotine Inhalers, Nicotine Replacement Therapies, Nicotine Sublingual Tablets

2) By Drug: Varenicline (Chantix), Bupropion (Zyban), Other Drugs

3) By Distribution: Drug Store, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Drug Therapy: Bupropion (Zyban), Varenicline (Chantix)

2) By E-Cigarettes: Disposable E-Cigarettes, Rechargeable E-Cigarettes, Pod Systems

3) By Nicotine Inhalers: Prescription Inhalers, Over-The-Counter Inhalers

4) By Nicotine Replacement Therapies (NRT): Nicotine Patches, Nicotine Gum, Nicotine Lozenges

5) By Nicotine Sublingual Tablets: Fast-Acting Sublingual Tablets, Extended-Release Sublingual Tablets

Which Trends Are Contributing To Changes In The Quit Smoking Drugs Market?

Major companies operating in the quit smoking drugs market are prioritizing the creation of new formulations and delivery methods, including generic tablets, to enhance their market leadership across regions and gain a competitive advantage. Generic varenicline tablets are non-branded forms of the medication that incorporate varenicline tartrate; these are bioequivalent to the initial branded product and are utilized for smoking cessation therapy. For instance, in January 2024, Lupin Limited, an India-based pharmaceutical company, launched new Varenicline tablets in the United States, which are available in 0.5 mg and 1 mg strengths. These tablets are the generic equivalents of Chantix tablets (0.5 mg and 1 mg) from PF Prism C.V. and are intended to assist in smoking cessation treatment. Functioning as a partial agonist of the nicotinic acetylcholine receptor, varenicline operates by stimulating the release of dopamine, which can mitigate withdrawal symptoms and cravings associated with nicotine addiction. This dual mechanism allows it to lessen the pleasurable effects of smoking while simultaneously offering some stimulation to minimize withdrawal effects.

Which Firms Are Influencing Competition In The Quit Smoking Drugs Market?

Major companies operating in the quit smoking drugs market are 22nd Century Group, Cipla Limited, Dr. Reddy’s Laboratories, GSK Plc., Johnson & Johnson, NJOY LLC, Perrigo Company Plc, Pfizer Inc., Philip Morris International, Glenmark Pharmaceuticals Limited, Zydus Cadila Healthcare Limited, BioCorRx Inc., Ennaid Therapeutics LLC, Fertin Pharma A/S, Hikma Pharmaceuticals PLC, IntelGenx Technologies Corp., Innovus Pharmaceuticals Inc., Gilla Inc., Rusan Pharma Ltd., Novartis AG

Get The Full Quit Smoking Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/quit-smoking-drugs-global-market-report

Which Region Is The Largest In The Quit Smoking Drugs Market?

North America was the largest region in the quit smoking drugs market in 2025. The regions covered in the quit smoking drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Quit Smoking Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/quit-smoking-drugs-global-market-report

Browse Through More Reports Similar to the Global Quit Smoking Drugs Market 2026, By The Business Research Company

Quit Smoking Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/quit-smoking-drugs-global-market-report

Nicotine Addiction Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/nicotine-addiction-treatment-global-market-report

Nicotine Addiction Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/nicotine-addiction-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795